Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M15.9Revenue (TTM) $M10.5Net Margin (%)-80.0Altman Z-Score-40.4
Enterprise Value $M13.5EPS (TTM) $-5.2Operating Margin %-78.6Piotroski F-Score5
P/E(ttm)--Beneish M-Score--Pre-tax Margin (%)-80.0Higher ROA y-yY
Price/Book--10-y EBITDA Growth Rate %--Quick Ratio0.6Cash flow > EarningsY
Price/Sales1.95-y EBITDA Growth Rate %0.1Current Ratio0.6Lower Leverage y-yY
Price/Free Cash Flow--y-y EBITDA Growth Rate %--ROA % (ttm)-676.4Higher Current Ratio y-yY
Dividend Yield %--PEG--ROE % (ttm)--Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M2.0ROIC % (ttm)--Gross Margin Increase y-yN

Gurus Latest Trades with OPNT

Number of guru portfolios checked: 68.
No Entry found in the selected group of Gurus. You can

OPNT is held by these investors:

No Entry found in the selected group of Gurus. You can
Premium Most recent portfolio changes are included for Premium Members only!


OPNT: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Sinclair MichaelExecutive Chairman, 10% Owner 2015-01-15Sell1,700$3.5128.57view
Sinclair MichaelExecutive Chairman, 10% Owner 2015-01-15Sell1,700$3.5128.57view
COHEN MARC AChairman,CEO,Treas, & Sec, 10% Owner 2012-06-14Sell243$2450-99.67view
KAISER RONALD WDirector 2012-06-06Sell100$2604-99.69view
KAISER RONALD WDirector 2010-12-08Sell100$2608-99.69view
Wesley Melvin IIICFO 2010-11-29Sell11$2424-99.67view
Wesley Melvin IIICFO 2010-11-18Sell23$2190-99.63view
COHEN ALAIN JPresident & Chief Tech Officer, 10% Owner 2010-07-27Sell2$1515-99.47view
COHEN MARC AChairman, CEO, Treas, & Sec, 10% Owner 2010-07-27Sell3$1515-99.47view
Wesley Melvin IIICFO 2010-07-27Sell1$1515-99.47view

Quarterly/Annual Reports about OPNT:

News about OPNT:

Articles On GuruFocus.com
No related article found.

More From Other Websites
OPIANT PHARMACEUTICALS, INC. Files SEC form 8-K, Other Events Sep 21 2016
Narcan Nasal Spray Inventor on U.S. Drug Epidemic Sep 15 2016
OPIANT PHARMACEUTICALS, INC. Files SEC form 8-K, Regulation FD Disclosure Sep 13 2016
OPIANT PHARMACEUTICALS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement,... Sep 08 2016
Opiant Pharmaceuticals to Present at the Rodman & Renshaw Conference on September 13 in New York... Aug 18 2016
They Developed A Disruptive Drug With Government Funding And Trade Crazy Cheap Aug 15 2016
They Developed A Disruptive Drug With Government Funding And Trade Crazy Cheap Aug 15 2016
[$$] Wonder Workshop Raises $20M Series B for Educational Robots Jul 28 2016
After $500 Million Exit, Pharma Experts Shift Focus To This Disruptive Company’s Product Jul 21 2016
After $500 Million Exit, Pharma Experts Shift Focus To This Disruptive Company’s Product Jul 21 2016
OPIANT PHARMACEUTICALS, INC. Financials Jun 14 2016
OPIANT PHARMACEUTICALS, INC. Files SEC form 10-Q, Quarterly Report Jun 08 2016
Opiant Pharmaceuticals, Inc. :OPNT-US: Earnings Analysis: Q2, 2016 By the Numbers : May 23, 2016 May 23 2016
OPIANT PHARMACEUTICALS, INC. Files SEC form 8-K, Change in Directors or Principal Officers,... May 11 2016
OPIANT PHARMACEUTICALS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement May 02 2016
OPIANT PHARMACEUTICALS, INC. Files SEC form 8-K, Change in Directors or Principal Officers,... Apr 15 2016
Opiant Pharmaceuticals, Inc. :OPNT-US: Earnings Analysis: Q2, 2016 By the Numbers Mar 22 2016
OPIANT PHARMACEUTICALS, INC. Files SEC form 10-Q, Quarterly Report Mar 15 2016
OPIANT PHARMACEUTICALS, INC. Files SEC form 8-K/A, Submission of Matters to a Vote of Security... Feb 17 2016
OPIANT PHARMACEUTICALS, INC. Financials Feb 06 2016

Add Notes, Comments

If you want to ask a question or report a bug, please create a support ticket.
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)